Trial Profile
A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer; Ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2007 Status changed from recruiting to completed.
- 08 Aug 2005 New trial record.